Category: Business
-
“Resonance Sensitivity”: The Rare and Differentiating Skillset That Makes Design a Deep Competitive Moat
by Jonathan A. Handler, MD, FACEP, FAMIA Design Can Be a Deep Competitive Moat People often claim physical design and user experience (together, for short, “design”) are easily copied by big companies and therefore not a competitive moat. Yet, that rarely seems to happen. Most products seem pretty “meh”. If great design is easily copied,…
-
Some of My Healthcare AI Thoughts as of 5/2026
by Jonathan A. Handler, MD, FACEP, FAMIA Here are some summaries of my thoughts on various topics related to healthcare AI as of 5/2026, mostly from a talk I recently gave at the Illinois Society of Health and Risk Management. These may include a mix of my opinions and facts. My thoughts and this content…
-
The WXP: My “Secret Weapon” Metric in Process Performance Analysis
by Jonathan A. Handler, MD, FACEP, FAMIA Introduction Throughout my professional life, I have performed analyses to assess performance related to some process or function. Whether it’s the performance of people processes, machine processes, or something else, I have found a simple metric (or set of similar metrics) that seems very often to tell me…
-
Predicting Correctly Seems More Often Luck Than Skill. I’m Making Some Healthcare Predictions Anyway.
by Jonathan A. Handler, MD, FACEP, FAMIA As of this writing (2025), there are about 8 billion people in the world. Let’s say that every person guesses the likelihood that “the stock market” (let’s say the S&P 500) will be up or down from one quarter to the next. And let’s say that this is…
-
The ANY YES and ALL YES Innovation Games
Why do innovations succeed or fail? Why do the roots of so many innovations start in academic institutions, and why do big companies so often struggle with innovation? The math says it may depend on whether the innovator is playing an ALL YES or an ANY YES innovation game.
-
The “Hard Dollar Delusion”: losing touch with the reality of “soft” dollars
Primarily because they are easier to measure, some consider “hard dollars” more “real” and therefore more likely to drive their business decisions than “soft dollars,” even when soft dollars have a greater impact on the business. As a result, business and clinical outcomes can be adversely affected.
Zero Effectors 